Gallagher Capital Advisors LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Gallagher Capital Advisors LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 24.7% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 19,064 shares of the company's stock after buying an additional 3,780 shares during the period. Novo Nordisk A/S comprises about 1.0% of Gallagher Capital Advisors LLC's portfolio, making the stock its 27th largest holding. Gallagher Capital Advisors LLC's holdings in Novo Nordisk A/S were worth $1,324,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Victory Capital Management Inc. lifted its stake in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the period. North Star Investment Management Corp. boosted its stake in shares of Novo Nordisk A/S by 18.2% during the 1st quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after acquiring an additional 3,200 shares in the last quarter. Stanley Laman Group Ltd. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $390,000. Dover Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $505,000. Finally, SVB Wealth LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $1,250,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on NVO shares. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Trading Down 4.8%

Shares of NYSE NVO traded down $3.36 during mid-day trading on Wednesday, reaching $67.37. The company's stock had a trading volume of 13,591,048 shares, compared to its average volume of 7,190,667. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The stock has a 50-day moving average of $68.61 and a two-hundred day moving average of $77.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion during the quarter. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.